{"id":"NCT00929526","sponsor":"GlaxoSmithKline","briefTitle":"Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study","officialTitle":"Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2009-06-29","resultsPosted":"2012-10-15","lastUpdate":"2016-10-20"},"enrollment":752,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"PROCEDURE","name":"Liquid-based cytology (LBC) sampling","otherNames":[]},{"type":"PROCEDURE","name":"Blood sampling","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"},{"label":"Aimmugen Group","type":"PLACEBO_COMPARATOR"}],"summary":"This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated with human papillomavirus (HPV)-16 and/or HPV-18 or other oncogenic HPV types for an additional two years. All subjects who participated in the primary vaccination study NCT00316693 and who confirmed their interest in participating in a long term follow up study will therefore be invited to be followed for up to 48 months after administration of the first dose of vaccine. In addition, safety and persistence of the humoral immune response will be evaluated in this study.\n\nThis protocol posting deals with objectives \\& outcome measures of the extension phase at Months 36 and 48. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00316693).","primaryOutcome":{"measure":"Number of Subjects Reporting Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Cases Associated With HPV16 and/or HPV18 Detected Within the Lesional Component of the Cervical Tissue Specimen.","timeFrame":"From Month 0 up to Month 12","effectByArm":[{"arm":"Cervarix Group","deltaMin":0,"sd":null},{"arm":"Aimmugen Group","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":["31824976","25424783"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":375},"commonTop":[]}}